國家衛生研究院 NHRI:Item 3990099045/7584
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12190/12972 (94%)
造訪人次 : 1060854      線上人數 : 699
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/7584


    題名: A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity
    作者: Song, YC;Cheng, HY;Leng, CH;Chiang, SK;Lin, CW;Chong, P;Huang, MH;Liu, SJ
    貢獻者: Division of Vaccine Research and Development
    摘要: PELC is a novel emulsion-type adjuvant that contains the bioresorbable polymer poly (ethylene glycol)-block-poly (lactide-co-ε-caprolactone) (PEG-b-PLACL), Span?85 and squalene. To investigate whether PELC is able to enhance CTL responses of antigens for treating tumor, peptide or protein antigen derived from HPV16 E7 were formulated with PELC nanoparticles and CpG oligodeoxynucleotide. We identified that PELC formulation could delay release of antigens in vittro and in vivo. We assessed the immunogenicity of an H-2Db-restricted CTL epitope RAHYNIVTF (RAH) formulated with PELC or PELC/CpG and investigated the ability of these formulations to promote tumor regression. Following a single-dose subcutaneous injection in mice, we found that the RAH peptide formulated with PELC/CpG (RAH/PELC/CpG) resulted in increased numbers of IFN-γ-secreting cells and RAH-specific CD8+ T cells and an enhanced cytotoxic T cell response compared with RAH formulated with PELC or CpG alone. The tumor-bearing mice received a single-dose injection of RAH/PELC/CpG, which induced complete tumor regression. These results demonstrated that peptide antigen formulated with PELC/CpG nanoparticles is feasible for cancer immunotherapy.
    日期: 2014-01
    關聯: Journal of Controlled Release. 2014 Jan;173(1):158-165.
    Link to: http://dx.doi.org/10.1016/j.jconrel.2013.10.027
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0168-3659&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000329157100020
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84888319887
    顯示於類別:[劉士任] 期刊論文
    [黃明熙] 期刊論文
    [冷治湘] 期刊論文
    [莊再成] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    SDO0168365913008766.pdf881KbAdobe PDF675檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋